CIViC Evidence Items

21 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	CD274	Expression	Prognostic	Does Not Support	Poor Outcome	Lung Non-small Cell Carcinoma		Zhong et al., 2015
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Melanoma	Pembrolizumab,Nivolumab	Carbognin et al., 2015
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pembrolizumab,Nivolumab	Carbognin et al., 2015
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Atezolizumab,Pembrolizumab,Avelumab,Nivolumab	Passiglia et al., 2016
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Atezolizumab	Fehrenbacher et al., 2016
B	CD274	Expression	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Radiation Therapy	Skinner et al., 2017
B	CD274	Expression	Prognostic	Supports	Poor Outcome	Cancer		Wang et al., 2017
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pembrolizumab	Garon et al., 2015
B	CD274	Expression	Prognostic	Supports	Better Outcome	Lung Squamous Cell Carcinoma		Schmidt et al., 2015
B	CD274	Expression	Prognostic	Supports	Better Outcome	Ovarian Serous Carcinoma		Darb-Esfahani et al., 2016
B	CD274	Expression	Prognostic	Supports	Poor Outcome	Papillary Thyroid Carcinoma		Chowdhury et al., 2016
B	CD274	Expression	Prognostic	Supports	Better Outcome	Stomach Carcinoma		Böger et al., 2016
B	CD274	Expression	Predictive	Does Not Support	Sensitivity/Response	Melanoma	Ipilimumab,Nivolumab	Wolchok et al., 2013
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pembrolizumab	Reck et al., 2016
B	CD274	Expression	Prognostic	Supports	Poor Outcome	Breast Cancer		Zhang et al., 2017
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Atezolizumab,Pembrolizumab,Nivolumab,Durvalumab,Avelumab	Aguiar et al., 2017
B	CD274	Expression	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		Tokito et al., 2016
B	CD274	Expression	Predictive	Supports	Sensitivity/Response	Cancer	Nivolumab	Topalian et al., 2012
B	CD274	Expression	Predictive	Does Not Support	Sensitivity/Response	Merkel Cell Carcinoma	Pembrolizumab	Nghiem et al., 2016
B	CD274	Expression	Prognostic	Supports	Poor Outcome	Breast Cancer		Wang et al., 2017
B	CD274	Expression	Prognostic	Supports	Better Outcome	Cancer		Zhao et al., 2017